Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig + ZL-1310 in Poorly Differentiated NEC
NCT07707895Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Primary completion
- Apr 2030
- Countries
- 11
01
Overview
A Phase 2 trial of obrixtamig, zocilurtatug pelitecan in small cell lung cancer (SCLC), pulmonary large cell neuroendocrine carcinoma (LCNEC), extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Boehringer Ingelheim. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
obrixtamigzocilurtatug pelitecan
03
Conditions
small cell lung cancer (SCLC)pulmonary large cell neuroendocrine carcinoma (LCNEC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07707895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707895.